88 related articles for article (PubMed ID: 16843631)
1. Serum total cholesterol as a biomarker for Alzheimer's disease: mid-life or late-life determinations?
Panza F; Capurso C; D'Introno A; Colacicco AM; Vasquez F; Pistoia G; Capurso A; Solfrizzi V
Exp Gerontol; 2006 Sep; 41(9):805-6. PubMed ID: 16843631
[No Abstract] [Full Text] [Related]
2. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study.
Solomon A; Kåreholt I; Ngandu T; Winblad B; Nissinen A; Tuomilehto J; Soininen H; Kivipelto M
Neurology; 2007 Mar; 68(10):751-6. PubMed ID: 17339582
[TBL] [Abstract][Full Text] [Related]
3. Total cholesterol levels and the risk of mild cognitive impairment and Alzheimer's disease.
Panza F; Capurso C; D'Introno A; Colacicco AM; De Candia D; Capurso A; Solfrizzi V
J Am Geriatr Soc; 2007 Jan; 55(1):133-5. PubMed ID: 17233704
[No Abstract] [Full Text] [Related]
4. Cardiovascular disease and Alzheimer's disease: common links.
Stampfer MJ
J Intern Med; 2006 Sep; 260(3):211-23. PubMed ID: 16918818
[TBL] [Abstract][Full Text] [Related]
5. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
6. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.
Ray S; Britschgi M; Herbert C; Takeda-Uchimura Y; Boxer A; Blennow K; Friedman LF; Galasko DR; Jutel M; Karydas A; Kaye JA; Leszek J; Miller BL; Minthon L; Quinn JF; Rabinovici GD; Robinson WH; Sabbagh MN; So YT; Sparks DL; Tabaton M; Tinklenberg J; Yesavage JA; Tibshirani R; Wyss-Coray T
Nat Med; 2007 Nov; 13(11):1359-62. PubMed ID: 17934472
[TBL] [Abstract][Full Text] [Related]
7. Total serum cholesterol levels and Alzheimer's dementia in patients with Down syndrome.
Prasher VP; Airuehia E; Patel A; Haque MS
Int J Geriatr Psychiatry; 2008 Sep; 23(9):937-42. PubMed ID: 18395888
[TBL] [Abstract][Full Text] [Related]
8. Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men.
Chu LW; Tam S; Lee PW; Wong RL; Yik PY; Tsui W; Song Y; Cheung BM; Morley JE; Lam KS
Clin Endocrinol (Oxf); 2008 Apr; 68(4):589-98. PubMed ID: 17973937
[TBL] [Abstract][Full Text] [Related]
9. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
Hernanz A; De la Fuente M; Navarro M; Frank A
Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
[TBL] [Abstract][Full Text] [Related]
10. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.
Song F; Poljak A; Smythe GA; Sachdev P
Brain Res Rev; 2009 Oct; 61(2):69-80. PubMed ID: 19464319
[TBL] [Abstract][Full Text] [Related]
11. The influence of age on the association between cholesterol and cognitive function.
van Vliet P; van de Water W; de Craen AJ; Westendorp RG
Exp Gerontol; 2009; 44(1-2):112-22. PubMed ID: 18579327
[TBL] [Abstract][Full Text] [Related]
12. [Homocysteine--marker of vascular disease in elderly with mental illness].
Hultberg B; Nilsson K; Gustafson L
Lakartidningen; 2008 Sep 17-23; 105(38):2576-8. PubMed ID: 18846861
[No Abstract] [Full Text] [Related]
13. Fatty acids, lipid metabolism and Alzheimer pathology.
Hooijmans CR; Kiliaan AJ
Eur J Pharmacol; 2008 May; 585(1):176-96. PubMed ID: 18378224
[TBL] [Abstract][Full Text] [Related]
14. [Biomarkers in cerebrospinal fluid and blood in memory complaints].
Zetterberg H; Andreasen N; Blennow K
Lakartidningen; 2009 May 13-19; 106(20):1386-9. PubMed ID: 19585836
[No Abstract] [Full Text] [Related]
15. Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment.
Lee KS; Chung JH; Lee KH; Shin MJ; Oh BH; Hong CH
Immunol Lett; 2008 Dec; 121(2):105-9. PubMed ID: 18930766
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers in preclinical Alzheimer's disease.
Chong MS; Lim WS; Sahadevan S
Curr Opin Investig Drugs; 2006 Jul; 7(7):600-7. PubMed ID: 16869111
[TBL] [Abstract][Full Text] [Related]
17. Detection of prodromal Alzheimer's disease.
Mortimer JA; Petersen RC
Ann Neurol; 2008 Nov; 64(5):479-80. PubMed ID: 19067352
[No Abstract] [Full Text] [Related]
18. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment.
Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM
Free Radic Res; 2008 Feb; 42(2):162-70. PubMed ID: 18297609
[TBL] [Abstract][Full Text] [Related]
19. Methodology for discovery of Alzheimer's disease blood-based biomarkers.
Maes OC; Schipper HM; Chertkow HM; Wang E
J Gerontol A Biol Sci Med Sci; 2009 Jun; 64(6):636-45. PubMed ID: 19366883
[TBL] [Abstract][Full Text] [Related]
20. AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease.
Lovestone S; Francis P; Kloszewska I; Mecocci P; Simmons A; Soininen H; Spenger C; Tsolaki M; Vellas B; Wahlund LO; Ward M;
Ann N Y Acad Sci; 2009 Oct; 1180():36-46. PubMed ID: 19906259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
